A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors

PURPOSE: BMS-690514 is a novel oral tyrosine kinase inhibitor of ErbB and vascular endothelial growth factor receptor. This open-label phase I dose-escalation study (ClinicalTrials.gov Identifier: NCT00516451) aimed to assess the safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nokihara, Hiroshi, Yamamoto, Noboru, Yamada, Yasuhide, Yamada, Kazuhiko, Hirata, Taizo, Goto, Yasushi, Tanioka, Maki, Ikeda, Yoko, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456941/
https://www.ncbi.nlm.nih.gov/pubmed/22878519
http://dx.doi.org/10.1007/s00280-012-1932-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456941/
https://www.ncbi.nlm.nih.gov/pubmed/22878519
http://dx.doi.org/10.1007/s00280-012-1932-9

Ejemplares similares